Basel beats 2021 financial guidance on preliminary revenue and year-end cash position

Basel beats 2021 financial guidance on preliminary revenue and year-end cash position

David Veitch, Chief Executive Officer, commented: “We are very pleased with the significantly increased non-deferred revenue contributions from Cresemba and Zevtera, which are reflecting the continued progress that we, together with our partners, are making in the commercialization of our brands. Global in-market sales of Cresemba have exceeded 300 million US dollars in the 12 months to the end of September 2021. The continued commercial success of Cresemba, as well as the progress made in making Cresemba available in Japan and China have triggered several sales, development and regulatory milestone payments to Basilea throughout 2021.” At half-year reporting 2021, Basilea had guided for non-deferred revenue contributions from Cresemba and Zevtera of CHF 115 – 125 million, total revenue of CHF 134 – 144 million and a year-end cash position of CHF 142 – 147 million (CHF 165 – 170 million, excluding the impact from the reduction of convertible bonds in FY 2021). Story continues

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced today the unaudited preliminary revenue and year-end cash-position for the financial year 2021. Total revenue, non-deferred revenue contributions from Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) and year-end cash and financial investments are all above guidance. Basel, January 10, 2022

Non-deferred revenue contributions from Basilea’s marketed products, the antifungal Cresemba and the antibiotic Zevtera, are expected to have increased by 65% to approximately CHF 129 million (FY 2020: CHF 78.2 million). Total revenue, including revenue contributions from Cresemba and Zevtera as well as BARDA reimbursements, offsetting ceftobiprole phase 3 development expenses and other revenue contributions, is expected to amount to approximately CHF 148 million (FY 2020: CHF 127.6 million). Basilea also reported preliminary CHF 150 million cash and financial investments at year-end 2021 or CHF 173 million, excluding the impact from the reduction of outstanding convertible bonds. Ad hoc announcement pursuant to Art. 53 LR

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have several preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. Disclaimer About Basilea

The audited full financial statements as well as the annual report 2021 will be published on February 15, 2022. The final audited revenue for 2021 and the cash position as of year-end 2021 may differ from the preliminary reported numbers. Adesh Kaul, Chief Financial Officer, added: “The impressive growth in our Cresemba and Zevtera non-deferred revenue is indicative of the robust global in-market performance of our brands and the continued regulatory progress made by our partners with regard to accessing new markets. We are looking forward to the key milestones for our anti-infectives franchise in 2022, including anticipated regulatory decisions for Cresemba in China and Japan and the results of our phase 3 ERADICATE study with ceftobiprole. Positive outcomes for these key milestones could have a significant positive mid-term impact on our commercial anti-infectives business. Our strong year-end cash position and the reduction of the outstanding convertible bonds provide us with the required financial flexibility to execute on our strategic priorities.”

The News Highlights

  • Basel beats 2021 financial guidance on preliminary revenue and year-end cash position
  • Check the latest News news updates and information about business, finance and more.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Third quarter GNP net profit more than doubled to Rs 1,127 crore
Third quarter GNP net profit more than doubled to Rs 1,127 crore
Punjab National Bank (PNB) announced a two-fold increase in standalone net profit for the third quarter ended December at Rs 1,126.78 crore on Thursday. In ...
SAP software group buys majority stake in American fintech Taulia
SAP software group buys majority stake in American fintech Taulia
While SAP did not disclose the deal price, SAP Chief Executive Officer Christian Klein said the value is less that $1 billion. Taulia had raised more than ...
How Brazil is reforming a public fund to finance broadband expansion
Stockton wants to rebrand itself as a ‘business-friendly city’
The plan focuses on rebranding the city, supporting small businesses and attracting new business to the area.  “Telling our story, our rich history here in the ...
Kissht raises Rs 100 cr in funding led by Trifecta Capital, Northern Arc
Kissht raises Rs 100 cr in funding led by Trifecta Capital, Northern Arc
The company will utilise the funds to expand its scale of operations, enhance its product offerings including credit cards for small business/shops and ...
Chip shortage drives UK car production to a minimum after 1956
UK produces lowest number of cars since 1956 amid chip and virus crisis
The trade group expects a rebound to more than 1 million units this year as the components bottleneck eases and automakers from Stellantis NV to Nissan Motor ...
Flathead County to distribute free rapid COVID-19 tests at home
Flathead County to distribute free rapid COVID-19 tests at home
Additional information about COVID-129 in Flathead County can be found at https://www.flatheadhealth.org/. “Early testing is an effective method to prevent ...
Games for Android are finally making their way to Windows
Games for Android are finally making their way to Windows
Google officially launched beta testing for Android games on Windows a couple of days ago but the service was limited to 12 games in Hong Kong, Taiwan, and ...
Stealth omicron variant: should you care about BA.2?
Stealth omicron variant: should you care about BA.2?
What’s next: Scientists are keeping an eye on the BA.2 variant. Per CBS News, health officials hope to find out if it evades COVID-19 vaccines more or causes ...
BharatPe's PoS business exceeds annualized transaction value of $4 billion
BharatPe’s PoS business exceeds annualized transaction value of $4 billion
The segment now contributes about 25 per cent to the overall payments Transaction Processed Value (TPV) of the company. This growth can be attributed to the ...
What is COVID data telling us?  |  local news
What is COVID data telling us? | local news
Case counts trending down So what do scientists have to say about COVID cases, hospitalizations and our future with COVID? Cases appear to be trending down but ...
Show next
We will be happy to hear your thoughts

Leave a reply

Compsmag - Latest News In Tech and Business
Logo